Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Role of statins in the treatment of multiple sclerosis.
Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependent ion channels.
Interpretation and visualization of non-linear data fusion in kernel space: study on metabolomic characterization of progression of multiple sclerosis.
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.
Multiple Sclerosis: Validation of MR Imaging for Quantification and Detection of Iron.
Chronic cerebrospinal venous insufficiency: Case-control neurosonography results.
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
CCSVI and MS: no meaning, no fact.
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress.
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
IL-1β induces hypomyelination in the periventricular white matter through inhibition of oligodendrocyte progenitor cell maturation via FYN/MEK/ERK signaling pathway in septic neonatal rats.
An Empirical Investigation of a Biopsychosocial Model of Pain in Multiple Sclerosis.
Biomarkers in multiple sclerosis.
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis.
Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology.
The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.
Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination.
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
The cytokines cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) and ciliary neurotrophic factor (CNTF) differ in their receptor specificities.
Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave Dreams Study (Brain Venous Drainage Exploited Against Multiple Sclerosis): study protocol for a randomized controlled trial.
Association of multiple sclerosis susceptibility variants and early attack location in the CNS.
Pages
« first
‹ previous
…
173
174
175
176
177
178
179
180
181
…
next ›
last »